9 Meters Biopharma Inc. [NASDAQ: NMTR] traded at a low on 04/15/21, posting a -4.27 loss after which it closed the day’ session at $1.12. The company report on April 12, 2021 that 9 Meters Biopharma, Inc. and Celiac Disease Foundation Announce Collaboration to Support Clinical Trial Enrollment in 9 Meters’ Phase 3 CeDLara Study.
9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced that the Company will collaborate with the Celiac Disease Foundation (CDF) to support clinical trial enrollment in 9 Meters’ Phase 3 study, CeDLara, for their drug candidate larazotide in celiac disease.
9 Meters’ CeDLara study is a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of 9 Meters’ investigational drug, larazotide, for adult patients with at least a six-month history of celiac disease who continue to experience gastrointestinal symptoms despite maintaining a gluten-free diet for at least six months. Interim results and topline data readouts are anticipated in 2022.
The results of the trading session contributed to over 3483101 shares changing hands. Over the past one week, the price volatility of 9 Meters Biopharma Inc. stands at 6.45% while the volatility over the past one month is 10.01%.
The market cap for NMTR stock reached $277.18 million, with 216.07 million shares outstanding and 180.25 million shares in the current float. Compared to the average trading volume of 8.24M shares, NMTR reached a trading volume of 3483101 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about 9 Meters Biopharma Inc. [NMTR]?
The Average True Range (ATR) for 9 Meters Biopharma Inc. is set at 0.13 The Price to Book ratio for the last quarter was 5.60, with the Price to Cash per share for the same quarter was set at 0.15.
How has NMTR stock performed recently?
9 Meters Biopharma Inc. [NMTR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.88. With this latest performance, NMTR shares dropped by -34.88% in over the last four-week period, additionally plugging by 41.77% over the last 6 months – not to mention a rise of 143.69% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NMTR stock in for the last two-week period is set at 38.72, with the RSI for the last a single of trading hit 37.01, and the three-weeks RSI is set at 41.12 for 9 Meters Biopharma Inc. [NMTR]. The present Moving Average for the last 50 days of trading for this stock 1.5737, while it was recorded at 1.1320 for the last single week of trading, and 0.9902 for the last 200 days.
9 Meters Biopharma Inc. [NMTR]: Deeper insight into the fundamentals
Return on Total Capital for NMTR is now -165.11, given the latest momentum, and Return on Invested Capital for the company is -541.91. Return on Equity for this stock declined to -545.95, with Return on Assets sitting at -276.67. When it comes to the capital structure of this company, 9 Meters Biopharma Inc. [NMTR] has a Total Debt to Total Equity ratio set at 0.72. Additionally, NMTR Total Debt to Total Capital is recorded at 0.71, with Total Debt to Total Assets ending up at 0.59. Long-Term Debt to Equity for the company is recorded at 0.52, with the Long-Term Debt to Total Capital now at 0.52.
Reflecting on the efficiency of the workforce at the company, 9 Meters Biopharma Inc. [NMTR] managed to generate an average of -$5,124,707 per employee.9 Meters Biopharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.70 and a Current Ratio set at 5.70.
Earnings analysis for 9 Meters Biopharma Inc. [NMTR]
With the latest financial reports released by the company, 9 Meters Biopharma Inc. posted -0.13/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NMTR.
Insider trade positions for 9 Meters Biopharma Inc. [NMTR]
There are presently around $68 million, or 27.00% of NMTR stock, in the hands of institutional investors. The top three institutional holders of NMTR stocks are: ORBIMED ADVISORS LLC with ownership of 25,716,755, which is approximately 0% of the company’s market cap and around 1.00% of the total institutional ownership; ADAGE CAPITAL PARTNERS GP, L.L.C., holding 13,000,000 shares of the stock with an approximate value of $14.56 million in NMTR stocks shares; and VANGUARD GROUP INC, currently with $8.06 million in NMTR stock with ownership of nearly 839.418% of the company’s market capitalization.
Positions in 9 Meters Biopharma Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 38 institutional holders increased their position in 9 Meters Biopharma Inc. [NASDAQ:NMTR] by around 32,463,843 shares. Additionally, 13 investors decreased positions by around 1,519,939 shares, while 13 investors held positions by with 26,889,329 shares. The mentioned changes placed institutional holdings at 60,873,111 shares, according to the latest SEC report filing. NMTR stock had 22 new institutional investments in for a total of 22,140,858 shares, while 8 institutional investors sold positions of 424,020 shares during the same period.